Plot of major adverse events after 208 percutaneous cryoablation sessions of 310 lung tumors in 139 patients—versus session’s hospital length of stay

Plot of major adverse events after 208 percutaneous cryoablation sessions of 310 lung tumors in 139 patients—versus session’s hospital length of stay. Each circle represents one event. Shading of circle represents ventilation modality. Size of circle represents CTCAE grade. Major adverse events were defined as CTCAE grade ≥ 3. CTCAE, Common Terminology Criteria for Adverse Events. One grade 4 pneumothorax resulted in intraprocedural cardiac arrest due to impeded venous return. 

 


January 25, 2024 — According to the American Journal of Roentgenology (AJR), high-frequency jet ventilation appears to be as safe as spontaneous respiration (SR) for percutaneous lung ablation and could increase procedural efficiency, especially for complex cases. 

“HFJV appears to be as safe as SR but had longer room times,” clarified corresponding author and 2019 ARRS Scholar Florian J. Fintelmann, MD, from Massachusetts General Hospital in Boston. “HFJV can be used in complex cases without significantly impacting hospital length of stay (HLOS) longer than or equal to 2 days, procedure time, or radiation exposure.” 

This AJR accepted manuscript included consecutive adults who underwent CT-guided percutaneous cryoablation of one or more lung tumors with HFJV or SR (January 1, 2017–May 31, 2023). Fintelmann et al. compared major (grade ≥ 3) Common Terminology Criteria for Adverse Events (CTCAE) within 30 days and HLOS ≥ 2 days. Using generalized estimating equations, the AJR authors then compared procedure, room, and CT guidance acquisition times, CT guidance radiation and total radiation dosage, as well as pneumothorax. 

Ultimately, for 208 cryoablations of 310 lung tumors in 139 patients, HFJV—compared with SR—was more commonly used to treat multiple tumors per session (43% vs. 19%; p =.02) and non-peripheral tumors (48% vs. 24%; p <.001), without significant differences in major adverse event rates, procedure times, or radiation exposure (p > .05). 

“The choice of ventilation modality during percutaneous lung ablation should be based on patient characteristics and anticipated procedural requirements, as well as operator preference,” Fintelmann et al. added

For more information: www.arrs.org


Related Content

News | Breast Imaging

March 10, 2026 — QT Imaging Holdings has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an ...

Time March 13, 2026
arrow
News | Lung Imaging

March 11, 2026 — Noah Medical has announced the publication of the MATCH 2 study in the international, peer-reviewed ...

Time March 12, 2026
arrow
News | Stroke

March 11, 2026 — Brainomix, a provider of AI-powered imaging tools for stroke and lung fibrosis, has announced the ...

Time March 11, 2026
arrow
News | Computed Tomography (CT)

March 5, 2026 — At ECR 2026, Royal Philips introduced Rembra, its next-generation radiology CT system designed for the ...

Time March 09, 2026
arrow
Feature | Artificial Intelligence | Kyle Hardner

Once considered an adjunct brain cancer therapy and a last-resort treatment, noninvasive radiosurgery has evolved ...

Time March 09, 2026
arrow
News | Radiation Oncology

March 4, 2026 — Lunit has announced that 21 studies featuring its AI solutions will be presented at the European ...

Time March 05, 2026
arrow
News | Artificial Intelligence

March 2, 2026 — RadNet, Inc. has acquired Gleamer SAS, a radiology AI company based in Paris, France. Gleamer will be ...

Time March 03, 2026
arrow
News | Ultrasound Imaging

March 2, 2026 — Esaote Group will officially launch the new MyLab E85 and MyLab C30 GTS Edition ultrasound systems at ...

Time March 02, 2026
arrow
News | Remote Viewing Systems

Feb. 26, 2026 — DeepHealth, Inc., a provider of AI-powered health informatics and a wholly owned subsidiary of RadNet ...

Time February 27, 2026
arrow
News | FDA

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Time February 26, 2026
arrow
Subscribe Now